about
LeprosyAdjuvants and antibody production: dispelling the myths associated with Freund's complete and other adjuvantsEffects of 2,4,5-trichlorophenoxyacetic acid, pentachlorophenol, methylprednisolone, and Freund's adjuvant on 2-hydroxyethylnitrosourea carcinogenesis in MRC-Wistar ratsPrimary immune response to liposomal tetanus toxoid in mice: the effect of mediatorsCharacterization of glycolytic enzymes--rAldolase and rEnolase of Leishmania donovani, identified as Th1 stimulatory proteins, for their immunogenicity and immunoprophylactic efficacies against experimental visceral leishmaniasisPrevention of peripheral tolerance by a dendritic cell growth factor: flt3 ligand as an adjuvant.Screening for potential adjuvants administered by the pulmonary route for tuberculosis vaccines.Differential regulation of macrophage interleukin-1 (IL-1), IL-12, and CD80-CD86 by two bacterial toxins.Multiple effects of immunostimulatory DNA on T cells and the role of type I interferons.Defined synthetic vaccines.Tolerance is established in polyclonal CD4(+) T cells by distinct mechanisms, according to self-peptide expression patterns.Current approaches to vaccine preparation.Protection against experimental autoimmune myocarditis is mediated by interleukin-10-producing T cells that are controlled by dendritic cellsNonionic block polymer surfactants modulate the humoral immune response against Streptococcus pneumoniae-derived hexasaccharide-protein conjugates.Adjuvants et stimulants de l'immunité: propriétés immunorégulatrices du muramyl-dipeptide, des corynébactéries anaérobies et du diéthyldithiocarbamate de sodiumDermal inflammation elicited by synthetic analogs of Treponema pallidum and Borrelia burgdorferi lipoproteins.Immunomodulatory properties of porins of some members of the family Enterobacteriaceae.Immunization with a recombinant C-terminal fragment of Plasmodium yoelii merozoite surface protein 1 protects mice against homologous but not heterologous P. yoelii sporozoite challenge.Studies on the induction of pharmacological responses to des-Arg9-bradykinin in vitro and in vivo.Enhanced antigen immunogenicity induced by bispecific antibodies.T cell priming versus T cell tolerance induced by synthetic peptides.Preferential accumulation of antigen-specific effector CD4 T cells at an antigen injection site involves CD62E-dependent migration but not local proliferation.Vaccine-induced immunity against cutaneous leishmaniasis in BALB/c mice.Recombinant human migration inhibitory factor has adjuvant activity.Antigen targeting to myeloid-specific human Fc gamma RI/CD64 triggers enhanced antibody responses in transgenic mice.The anatomy of T-cell activation and tolerance.In planta production of plant-derived and non-plant-derived adjuvants.Adjuvants.For better or for worse: the immune response against Mycobacterium tuberculosis balances pathology and protection.Effector T cells in rheumatoid arthritis: lessons from animal models.Muramyl dipeptide and its derivatives: peptide adjuvant in immunological disorders and cancer therapy.Prospects for the treatment of B cell tumors using idiotypic vaccination.Synthetic low-toxicity muramyl dipeptide and monophosphoryl lipid A replace Freund complete adjuvant in inducing growth-inhibitory antibodies to the Plasmodium falciparum major merozoite surface protein, gp195.Recombinant Leishmania tarentolae encoding the HPV type 16 E7 gene in tumor mice model.Vaccines for the future--an update.Nonionic block polymer surfactants enhance immunogenicity of pneumococcal hexasaccharide-protein vaccines.Immunoprotective responses of T helper type 1 stimulatory protein-S-adenosyl-L-homocysteine hydrolase against experimental visceral leishmaniasis.Vaccine delivery systems: potential methods for use in antifertility vaccines.Tuberculosis: the return of an old enemy.Immunological consequences of stress-related proteins--cytosolic tryparedoxin peroxidase and chaperonin TCP20--identified in splenic amastigotes of Leishmania donovani as Th1 stimulatory, in experimental visceral leishmaniasis.
P2860
Q24617200-2D1C7402-96D3-4719-92CE-8E5E0120650FQ28256294-A287CEFA-9266-4DA7-BAC4-71B820547F73Q28334631-9B59C807-3E36-430D-AA0E-0CAAD54A1182Q28341448-89AC5C80-3B06-451C-9E50-126FD4C87D95Q28539119-7144A95F-3D84-471E-944D-32C9D7DAFA2DQ33368912-597994BD-43AF-49DE-B60D-A900224B293EQ33416980-8D26B814-D58B-44E4-A883-42F868870B7BQ34002122-B9F0D362-7AB8-4550-B0F0-7AC975BE345AQ34005409-07D0C0AE-6F39-42C4-8896-00A22D8EA7A1Q34280941-C8EC15C3-A2B9-4BB2-A10A-514F4CED6F8EQ34507271-10DBA2A7-3887-49AD-AD7C-79E8FCCC7ACAQ34688016-3A282490-DD7E-419A-BEF8-C713CD6B3BD9Q35084902-8FE676CC-C8B1-4F0C-9F1E-FFC733F2B78AQ35101711-94B9906C-85B2-4FB0-B606-A23A5E151577Q35192565-0588755D-2BC2-4AEF-8399-A7BB4DD724BAQ35403982-85896CB4-0AD4-491E-9BE7-9C159F359EA7Q35549669-1D1A81E3-2AE6-42D2-BD7F-538505995B26Q35557454-FF8E3DA8-29A8-4369-B3F1-449C5DC57B58Q35754972-31CC434C-2409-43D7-B399-735FBBC711E0Q36351292-50B7BD28-826F-492B-BAE5-4B857CE600BEQ36365135-08043D8B-2D17-4ED3-A1BB-F4ABE1D3875AQ36370576-9CD15AE4-366F-416D-BB07-0D822D523B7EQ36995828-B24C00F1-5EB2-4745-8C7E-4AC86276EE8EQ37175910-02FFE581-DFC4-4907-AF87-2B6D22CC6707Q37350204-950F00D5-CEDB-4633-A055-530AE38F87EAQ37688958-689002F9-0E3F-4686-89A7-F7C26C9B6E4DQ37776716-004C3260-09F4-4177-988C-2CCA799809E4Q37844069-117C7975-7460-4FA7-9268-24B37951CF86Q37846876-D7F5FC05-B05E-416A-BB82-0B3517A3E258Q37868325-87D7DD3F-FB87-4853-A449-DDC50D76CF6AQ37969751-2E334F8D-BD2E-44A3-BC98-473D47129737Q38246920-085B1450-234B-4579-9936-7B2EF2855BF5Q39086032-D29A3464-09F8-4852-A6AD-F28F31ED7D60Q39235934-D7675306-EC3D-4362-9804-A0BEDBAA48A4Q39596006-F380E9A2-60A7-438A-AF2A-2F083B9AE36DQ40160043-F1A94871-3329-4AD3-8D73-B9CD1439BCFFQ40783439-9369677C-9297-48A7-AE95-6FA031BF886AQ40847031-5272090F-3CB7-4FCC-B619-338F8D29061CQ40901255-3A918ADE-49B0-4BC5-A78F-A34989D5D02DQ41603970-7DE2F95D-2A86-4916-BCF2-1A9C9F470580
P2860
description
1986 nî lūn-bûn
@nan
1986年の論文
@ja
1986年学术文章
@wuu
1986年学术文章
@zh-cn
1986年学术文章
@zh-hans
1986年学术文章
@zh-my
1986年学术文章
@zh-sg
1986年學術文章
@yue
1986年學術文章
@zh
1986年學術文章
@zh-hant
name
Current status of immunological adjuvants.
@en
Current status of immunological adjuvants.
@nl
type
label
Current status of immunological adjuvants.
@en
Current status of immunological adjuvants.
@nl
prefLabel
Current status of immunological adjuvants.
@en
Current status of immunological adjuvants.
@nl
P2093
P1476
Current status of immunological adjuvants.
@en
P2093
P304
P356
10.1146/ANNUREV.IY.04.040186.002101
P577
1986-01-01T00:00:00Z